If you missed the first story, check it out here: New HIV Prevention Drug?
A US Food and Drug Adminsitration (FDA) advisory committee has recommended Gilead Sciences’ Truvada for approval in the US in the prevention of HIV, as well as in combination with three other therapies, as Quad, for the treatment of the virus.
The panel voted in favour of approving Truvada (emtricitabine and tenofovir disoproxil fumarate) to reduce the risk of HIV-1 infection among uninfected adults, an HIV prevention strategy called pre-exposure prophylaxis (PrEP).
This indication was divided into three different sub-groups: men who have sex with men, non-infected partners of people with HIV, and other individuals at risk for acquiring HIV through sexual activity. Voting results were 19 to 3, 19 to 2 (with one abstaining) and 12 to 8 (with two abstaining) respectively.
Read more »
